Siemens Ltd is considering joining the bidding for a project to supply trains for the new light-rail transit systems in New Taipei City (新北市) and Greater Kaohsiung next year, as part of its efforts to grow its local business, a company executive said yesterday.
Siemens currently supplies trains for the Kaohsiung Mass Transit System and the Taipei Mass Transit System’s Banciao-Nangang Line, Erdal Elver, chief executive officer of Siemens’ local branch, told a media gathering yesterday.
The company’s trains can help save 30 percent in energy consumption, Elver said.
However, there are constraints which could deter the company from placing a bid, including pricing, customers’ budget, timing and specifications, he said.
He said if those conditions meet the company’s plan, Siemens would bid for the project.
The Taipei City Government is scheduled to hold a bidding sometime next year for its light-rail transit system, which will to connect Taipei MRT’s Tamsui Line with less populated areas in Tamsui, New Taipei City.
Siemens’s Taiwan branch saw its revenue grow 6 percent year-on-year to NT$14 billion (US$482 million) in the fiscal year beginning October of last year, exceeding the company’s 2 percent expansion target.
The energy sector made up the biggest portion of its revenues last year, the company said.
Elver said the company expected its revenue growth for this year to be at least double the GDP growth of Taiwan.
In the first quarter of its 2013 fiscal year, Siemens is to begin two important collaborative projects with Taiwan’s industrial, academic and public sectors.
The company is scheduled to launch a Siemens machine tool controller technology application center in Greater Taichung next month to help its local machine tool partners upgrade their process technologies.
In the healthcare sector, the company said it planned to work with a local hospital to create a pioneering cardiovascular reference center in Asia to carry out academic research and clinical diagnosis, which would help Taiwan become an Asia-Pacific hub for cardiovascular disease research.